Xynomic Pharmaceuticals, Inc.
Clinical Trials
12
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation
- Conditions
- MelanomaNonsmall Cell Lung CancerCancerBRAF V600 MutationColorectal CancerThyroid Cancer
- Interventions
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Xynomic Pharmaceuticals, Inc.
- Target Recruit Count
- 221
- Registration Number
- NCT05275374
A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Xynomic Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04024696
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳Tianjin Medical University General Hospital, Tianjin, China
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Xynomic Pharmaceuticals, Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT03936153
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
🇨🇳China-Japan Friendship Hospital, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, China
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
- First Posted Date
- 2019-05-02
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Xynomic Pharmaceuticals, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT03934567
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
🇨🇳China-Japan Friendship Hospital, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, China
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Xynomic Pharmaceuticals, Inc.
- Target Recruit Count
- 139
- Registration Number
- NCT03600441
- Locations
- 🇺🇸
Advocate Medical Group - Park Ridge, Luther Lane - Oncology, Park Ridge, Illinois, United States
🇺🇸Norton Cancer Institute - St. Matthews Campus, Louisville, Kentucky, United States
🇺🇸Clinical Research Alliance Inc, Lake Success, New York, United States
- Prev
- 1
- 2
- Next